Also trades as: 4587.T (JPX) · $vol 7M
PPTDF OTC
PeptiDream Inc.
1W: +7.2%
1M: +4.1%
3M: +21.5%
YTD: -41.6%
1Y: -34.3%
3Y: -39.8%
5Y: -85.3%
$7.29
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$936.7M
52W Range5.88-12.85
Volume3,825
Avg Volume167
Beta0.55
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOPatrick Crawford Reid
Employees645
SectorHealthcare
IndustryBiotechnology
IPO Date2014-08-20
Websitepeptidream.com
3-25-23 Tonomachi
Kawasaki, KN 210-0821
JP
Kawasaki, KN 210-0821
JP
81 4 4270 1300
About PeptiDream Inc.
PeptiDream Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative therapeutic solutions, including constrained peptides, small molecules, and peptide-drug conjugates. The company utilizes its exclusive Peptide Discovery Platform System (PDPS), an advanced drug discovery engine, to propel the development of its peptide-based product pipeline. PeptiDream also maintains a collaborative research initiative and an exclusive licensing agreement with Takeda Pharmaceutical Company Limited, specifically focused on developing peptide-drug conjugates for neuromuscular disorders. Founded in 2006, the company's operations are based in Kawasaki, Japan.
Latest News
PeptiDream Inc. (OTCMKTS:PPTDF) Short Interest Update
PeptiDream Inc. (PPTDF) Q4 2025 Earnings Call Transcript
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
Recent Insider Trades
No insider trades found